Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study.

MLA

Buisson, Anthony, et al. “Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: The REMSWITCH Study.” Clinical Gastroenterology & Hepatology, vol. 21, no. 9, Aug. 2023, p. 2338. EBSCOhost, https://doi.org/10.1016/j.cgh.2022.08.011.

APA

Buisson, A., Nachury, M., Reymond, M., Yzet, C., Wils, P., Payen, L., Laugie, M., Manlay, L., Mathieu, N., Pereira, B., & Fumery, M. (2023). Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. Clinical Gastroenterology & Hepatology, 21(9), 2338. https://doi.org/10.1016/j.cgh.2022.08.011

Chicago

Buisson, Anthony, Maria Nachury, Maud Reymond, Clara Yzet, Pauline Wils, Laure Payen, Marie Laugie, et al. 2023. “Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: The REMSWITCH Study.” Clinical Gastroenterology & Hepatology 21 (9): 2338. doi:10.1016/j.cgh.2022.08.011.